EAM
TSHA icon

Exome Asset Management’s Taysha Gene Therapies TSHA Stock Holding History

Exome Asset Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-693,300
Closed -$1.23M – 73
2023
Q4 		$1.23M Buy
+693,300
New +$1.38M 1.21% 32

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Exome Asset Management's TSHA Position: Q1 2024 in Review

Exome Asset Management sold out of Taysha Gene Therapies (TSHA) in Q1 2024, closing a stake of 693,300 shares — an estimated $1.23M sold.

Exome Asset Management first reported a position in TSHA in Q4 2023 and held it in 1 quarter. The position peaked at $1.23M in Q4 2023. 109 funds tracked by Wall St. Rank hold TSHA as of Q1 2024.

  • Exome Asset Management reported no remaining Taysha Gene Therapies position as of Q1 2024 after selling out during the quarter.
  • Exome Asset Management sold 693,300 Taysha Gene Therapies shares in Q1 2024, an estimated $1.23M.
  • Exome Asset Management first reported a position in Taysha Gene Therapies in Q4 2023 and held it in 1 quarter.
  • Exome Asset Management's Taysha Gene Therapies position peaked at $1.23M in Q4 2023.
  • 109 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2024.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.